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Abstract
Background: The impact of sarcopenia on health-related quality of life (HRQoL) in community dwelling older people in Australia is not known. The aim of this 
study was to evaluate the relationship between sarcopenia and HRQoL in older Australian men and women.
Methods: 357 men and 370 women aged 65 years and older from the North West Adelaide Health Study at Stage 2 (2002-2004). Sarcopenia was defined as the 
presence of low muscle mass and low grip strength. HRQoL was assessed using the Short Form-36 (SF-36) questionnaire: physical component summary (PCS) 
and mental component summary (MCS). Analyses were performed using multiple regression and adjustments were made for age, physical activity, smoking status, 
co-morbidity and depression. 
Results: The prevalence of sarcopenia was 10.1% in men and 9.5% in women. Men with sarcopenia was significantly associated with the PCS score in the unadjusted 
model (P = 0.012) and only model 1 adjusted for age (P = 0.041). No significant association was noted in model 2 (model 1 + physical activity and smoking status) and 
model 3 (model 2 + Charlson co-morbidity index and depression). In men, a significant association between sarcopenia and MCS score was seen in the unadjusted 
and all 3 adjusted models. No association was seen between sarcopenia and the PCS or MCS score in women for both the adjusted and unadjusted models.
Conclusion: After adjusting for multiple confounders, the association between sarcopenia only remained for the MCS score, in men.  No association between 
sarcopenia and HRQoL was seen in women. 
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Introduction
Sarcopenia, the age-associated loss of skeletal muscle mass and 
function [1] is as a result of multiple interacting intrinsic (i.e. chronic 
inflammatory states) and extrinsic (i.e. decreased physical activity) 
factors [2]. Sarcopenia is also an independent risk factor for adverse 
health outcomes and is not limited to disability [3,4],  mortality [5,6], 
falls and fractures and hospitalization [7]. In one American study, the 
impact of sarcopenia on direct health care cost was staggering at $18 
billion in 2000 [8]. The same study postulated that a 10% reduction 
in sarcopenia prevalence through interventions that maintain or slow 
the progression of the loss of muscle mass, such as adequate protein 
intake and increased physical activity coupled with resistance exercise 
could potentially save $1.1 billion per year in healthcare costs [8]. 
Sarcopenia affects one in five older people aged 80 years and over and 
with population ageing, the health burden arising from sarcopenia will 
only increase if left unaddressed [9]. Doing nothing is not an option as 
this will be unaffordable. 
In older age, it is about the quality of life rather than the quantity 
of life. Quality of life to an older person is the ability to achieve a 
contented, meaningful, and fulfilling life [10]. Health related quality of 
life (HRQoL) is a multidimensional concept involving the subjective 
assessment of various dimensions of an individual’s health status 
including physical function, mental or psychological status, bodily 
pain, emotional wellbeing, functional capacity, occupational function, 
and social integration [11]. 
There is currently no one definition for sarcopenia. Since 2010, 
there has been six consensus papers published [1,12-16], of which it 
appears that the European Working Group on Sarcopenia in Older 
People (EWGSOP) [1] definition is the most widely utilised. Generally 
speaking, there are two key elements to the diagnosis of sarcopenia: the 
presence of a low appendicular skeletal muscle mass (ASM) and either 
low grip strength or low muscle performance. 
Both the EWGSOP [1] and the Asian Working Group on Sarcopenia 
(AWGS) [15] have proposed that quality of life should be one of the 
primary outcomes for future sarcopenia intervention trials. We have 
recently reported that the impact of sarcopenia on quality of life in 
older people has not been sufficiently explored, especially through 
prospective observational research [17]. To date, two cross sectional 
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and less than 20 kg for females [21]. These gender specific cut-off values 
for poor grip strength were used as these values had been shown to 
correspond to a low gait speed of less than 0.8 m/s [22].  
Definition of sarcopenia
Sarcopenia was defined as the presence of low muscle mass in 
conjunction with low hand grip strength [1].
Measurement of HRQoL
The participants HRQoL was assessed using the generic SF-36 
quality of life (QoL) instrument [23]. The SF-36 is a self-reported 
health questionnaire, consisting of 36 items, which is designed to assess 
an individual’s perceived health status across eight domains: Physical 
Functioning (PF), Role Physical (RP), Bodily Pain (BP), General Health 
(GH), Vitality (VT), Social Functioning (SF), Role Emotional (RE), and 
Mental Health (MH). From these eight health domains, two summary 
scores are derived which are the Physical Component Summary (PCS) 
scores (aggregate scores for PF, RP, GH, and BP), and the Mental 
Component Summary (MCS) scores (aggregate scores for VT, SF, RE, 
and MH). Categorical response options are used for all the items. The 
responses to each item within a domain are summated to generate 
a score between 0 – 100, with lower scores corresponding to poorer 
health status. 
Statistical analysis
Analyses were carried out for all subjects as well as for males 
and females separately. Data were reported as means and standard 
deviations (SD) for continuous variables and relative frequencies for 
categorical variables. For continuous variables (i.e. SF-36 QoL scores), 
differences in mean values between sarcopenic and non-sarcopenic 
groups were assessed by an independent samples t-test.  Chi-square 
test was utilised for nominal variables (co-morbidities and risk factors). 
The participants’ co-morbidities were categorised using the Charlson 
Comorbidity Index (CCI) [24], which is a measure of an individual’s 
disease burden. Multiple regression analysis was conducted to assess the 
association between the SF-36 quality of life domains with sarcopenia, 
with and without adjustment for confounding factors. Confounding 
factors included age, physical activity level, smoking status, CCI (score 
of one or more), and depression. SPSS 19 for Windows software (SPSS, 
Inc, Chicago, IL) was used for statistical analysis. A P - value of less than 
0.05 was considered statistically significant.
Results
727 subjects (out of 945 subjects from Stage 2; 357 males) aged 
65 years and older had both grip strength and DXA results at stage 2 
(Table 1, Supplementary Table S1).  Males and females were similar 
age; 73.9 ± 6.2 and 73.2 ± 6.0 years old respectively (P = 0.097). The 
prevalence of sarcopenia was 10.1% in males and 9.5% in females. For 
both genders, subjects with sarcopenia were significantly (all <0.001) 
older (79.0 ± 6.3 vs. 73.4 ± 5.9 years in males, and 76.9 ± 6.5 vs. 72.8 ± 
5.9 years in females), had a lower body mass index (24.1 ± 3.0 kg/m2 vs. 
28.1 ± 3.9 kg/m2 in males, and 23.4 ± 3.6 kg/m2 vs. 28.3 ± 4.6 kg/m2 in 
females), and had a smaller waist circumference (93.3 ± 9.9 cm vs. 101.8 
± 10.7 cm in males, and 83.6 ± 11.4 cm vs. 91.6 ± 11.3 cm in females), 
compared to non-sarcopenic subjects. In both genders, there were no 
significant differences in the prevalence of various co-morbidities and 
risk factors between sarcopenic and non-sarcopenic groups. 
Univariate analyses of the various SF-36 quality of life domains for 
sarcopenic and non-sarcopenic subjects are presented in Table 2 and 
Supplementary Table S2. In all subjects, sarcopenic individuals had 
studies investigating the association between sarcopenia and poor 
HRQoL in community dwelling older people have used the EWGSOP 
criteria [18,19]. There is a case for more research.
Our research aims to address this knowledge gap and the aim of our 
study is to assess the impact of sarcopenia (as defined by low muscle 
mass and low grip strength) on quality of life in community dwelling 
older South Australians, and also to determine whether there is any 
gender difference for this condition.
Methods
Study design and participants
This study had ethics approval from the Central Northern Adelaide 
Health Service Ethics of Human Research Committee (approval 
number: HREC/14/TQEH/276).
This is a cross-sectional study of community dwelling subjects aged 
65 years and older from Stage 2 (2002-2004) of North West Adelaide 
Health Study (NWAHS). The characteristic of the NWAHS cohort and 
the recruitment method had been described in detail elsewhere but is 
briefly discussed here [20]. 
All households in the north-western area of Adelaide with a 
telephone connected and the telephone number listed in the Electronic 
White Pages were randomly selected for the study. The participants 
responded to a telephone interview conducted using computer-assisted 
telephone interview (CATI) technology, as well as completing a self-
administered questionnaire. Both the interview and questionnaire 
covered a broad range of issues including HRQoL, socio-demographic 
profile, medical and mental health problems, and risk factors. 
4060 adults aged 18 years and older were recruited and underwent 
baseline biomedical examination between December 1999 and July 
2003 (Stage 1). 3566 subjects participated in the follow-up study at 
4 years, between May 2004 and February 2006 (Stage 2). In Stage 2, 
3206 participants who had completed the interview and questionnaire 
attended the clinic for biomedical examination and investigations. 
This included measurements of blood pressure, anthropometric 
characteristics, grip strength, spirometry, and blood tests. Participants 
aged 50 years and over were invited to participate in the dual x-ray 
absorptiometry (DXA) investigation for osteoporosis. This current 
study included only Stage 2 participants who were 65 years and 
older with both dual absorptiometry x-ray (DXA) and grip strength 
measurements.  
Measurement of skeletal muscle mass
In the NWAHS cohort, a Lunar PRODIGY scanner (GE Medical 
Systems, Madison, WI) in conjunction with Encore 2002 software was 
used to assess ASM. The skeletal muscle index (SMI) was calculated in 
order to take into account the differences in muscle mass due to height 
(SMI = ASM/height2). In this current study, the cut-offs for low muscle 
mass was based on the gender specific lowest 20% of the SMI, which 
corresponds to a value of less than 7.34 kg/m2 in men, and less than 5.80 
kg/m2 in women [9]. 
Measurement of muscle strength
Grip strength was assessed by a grip dynamometer (Lafayette 
Instrument Company, Lafayette, IN), with the subjects sitting and their 
arm supported by a horizontal surface. The maximum grip strength was 
calculated from the mean of three readings from the dominant hand 
[20]. Low grip strength was defined by a value less than 30 kg for males, 
Woo T (2018) The association between sarcopenia and quality of life is different in community dwelling older Australian men and women









(n = 335) P - value
Anthropometry Mean (SD)
 Age (years) 79.0 (6.3) 73.4 (5.9)  < 0.001 76.9 (6.5) 72.8 (5.9) < 0.001
 BMI (kg/m2) 24.1 (3.0) 28.1 (3.9)  < 0.001 23.4 (3.6) 28.3 (4.6) < 0.001
 Waist circumference (cm) 93.3 (9.9) 101.8 (10.7)  < 0.001 83.6 (11.4) 91.6 (11.3) < 0.001
 ASM/height2 (kg/m2) 6.93 (0.33) 8.22 (0.78)  < 0.001 5.43 (0.33) 6.52 (0.72) < 0.001
 Grip strength (kg) 25.0 (4.4) 35.3 (8.4)  < 0.001 15.1 (3.7) 21.3 (6.4) < 0.001
Co-morbidities and risk factors % (n)
 Cardiovascular disease 44.4% (16) 30.1% (95) 0.078 27.3% (9) 35.5% (117) 0.347
 Depression 9.7% (3) 5.3% (15) 0.404 15.4% (4) 8.9% (25) 0.287
 Physical activity level
 Sedentary 34.6% (9) 30.0% (76)
0.795
58.6% (17) 40.8% (107)
0.253
 Low 23.1% (6) 29.6% (75) 24.1% (7) 29.4% (77)
 Moderate 30.8% (8) 32.8% (83) 17.2% (5) 26.0% (68)
 High 11.5% (3) 7.5% (19) 0.0% 3.8% (10)
Table 1. Baseline characteristics of subjects









(n = 335) P - value
SF-36 score*
Physical component summary score  57.0 (28.9)  67.8 (22.3)  0.012  55.3 (25.9)  64.0 (23.9)  0.060
Physical function  56.0 (30.6)  68.9 (24.7)  0.005  48.3 (24.3)  60.7 (25.8)  0.009
General health  55.9 (24.6)  63.6 (19.4)  0.033  58.6 (19.3)  64.2 (19.9)  0.130
Mental component summary score 72.4 (24.7) 81.8 (16.0)  0.002 71.2 (20.3) 78.1 (19.5)  0.051
Table 2. Univariate analysis of SF-36 quality of life domains for men and women
*Data reported as mean (standard deviation)
significantly lower quality of life scores in all of the SF-36 quality of 
life domains, including the PCS and MCS scores, compared to non-
sarcopenic subjects. When the data was analysed according to gender, 
only men with sarcopenia had statistically lower PCS and MCS scores 
compared to non-sarcopenic men. There was no statistical difference 
in both PCS and MCS scores between sarcopenic and non-sarcopenic 
women, though there was a strong trend for sarcopenic women to have 
lower PCS and MCS scores. In males, the PCS scores for sarcopenic and 
non-sarcopenic subjects were 57.0 ± 28.9 and 67.8 ± 22.3 respectively 
(P = 0.012). The MCS scores in sarcopenic and non-sarcopenic men 
were 72.4 ± 24.7 and 81.8 ± 16.0 respectively (P = 0.002). The PCS 
scores for sarcopenic females were 55.3 ± 25.9 compared to 64.0 ± 
23.9 in non-sarcopenic females (P = 0.060). In females, MCS scores for 
sarcopenic and non-sarcopenic subjects were 71.2 ± 20.3 and 78.1 ± 
19.5 respectively (P = 0.051). 
Multiple regression analysis of the association between sarcopenia 
and SF-36 quality of life domains are presented in Table 3 as well 
as Supplementary Tables S3, S4, S5, and S6. Sarcopenia was not a 
significant predictor of poorer PCS scores in all subjects, including men 
and women, after adjustment for all confounding variables (P = 0.487 in 
all subjects, P = 0.092 in men, and P = 0.609 in women). Sarcopenia was 
however, significantly associated with the MCS scores in all subjects 
and in men after adjustment for all confounding variables (P = 0.017 
in all subjects, P = 0.001 in men). For men, sarcopenia remained a 
significant predictor of poor HRQoL in multiple SF-36 quality of life 
domains after adjustment for all confounding variables. However, in 
women, the association between sarcopenia and SF-36 quality of life 
was lost after adjustments were made for confounding factors (i.e. there 
may be other factors that might potentially explain the poor quality of 
life in females other than sarcopenia).  
Discussion
The key findings from this research demonstrated a clear gender 
difference in the impact of sarcopenia (as defined by low muscle 
mass and low grip strength) on HRQoL in community dwelling 
older Australian people. After adjusting for multiple confounders, the 
association between sarcopenia only remained for the MCS score in 
men.  No association between sarcopenia and HRQoL was seen in 
women. Even though our study did not find an association between 
sarcopenia and HRQoL in unadjusted model for females, there was 
however a strong trend for both PCS and MCS scores, with the MCS 
score almost reaching significance at a P value of 0.051 in the unadjusted 
model. 
To date, there have been two cross-sectional studies reporting on 
the relationship between sarcopenia including low ASM and at least one 
performance measure and SF-36 HRQoL [18,19]. Both the Patel and 
Beaudart study complied with the EWSGOP criteria in that sarcopenia 
was defined as low muscle mass and either low muscle strength or low 
muscle performance (i.e. gait speed or short physical performance 
battery score). In our study however, gait speed was not available, and 
we relied on the combination of low muscle mass and low grip strength 
and this difference in method may partially account for the difference 
in prevalence figures reported. Our study found that 10.1% of men and 
9.5% of women were affected by sarcopenia. The cross-sectional study 
by Patel [18], which included 1787 community dwelling subjects in the 
United Kingdom demonstrated the prevalence of sarcopenia to be 4.6% 
in men and 7.9% in women but rather than DXA, skin fold thickness 
was used to assess muscle mass. Beaudart’s study [19], which focused 
on 534 community dwelling subjects in Belgium, reported a prevalence 
of sarcopenia of 11.8% in men and 14.9% in women. In the Patel study, 
sarcopenia was associated with poorer general health (GH) and physical 
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function (PF) scores in both men and women but no adjustment for 
confounding variables occurred. The Beaudart study did not report 
separately on men and women but noted that sarcopenic subjects 
had lower physical function scores than subjects with no sarcopenia. 
Similarly, our study also found an association between sarcopenia 
and PF scores in all subjects but unlike the Patel study where subjects 
were younger and muscle mass was assessed using skin fold thickness, 
this association was noted only in men and for both associations only 
when unadjusted for confounding variables. In the Beaudart study, no 
other association was noted between sarcopenia and any other domain 
of HRQOL. In contrast, we noted an association between sarcopenia 
and all measured domains for HRQOL (Supplementary Tables S3 and 
S4) and associations remained after adjustment for all confounding 
variables (i.e. model 3) for MCS, RE, and MH in all subjects. The 
Beaudart study utilised a different statistical method (i.e. logistic 
regression), adjusted for different co-variables (i.e. BMI, cognitive and 
nutritional status, number of medications) and as already discussed 
used different measures to define sarcopenia and collectively these 
might partially account for the differences in study findings.
Both the Patel and Beaudart study did not report on the composite 
PCS and MCS scores and in our study, all eight quality of life domains 
as well as the PCS and MCS scores of the SF-36 were included. The 
Patel study only investigated the association between sarcopenia and 
GH and PF domains in men and women. Our study demonstrated 
that after adjustment for confounders, only men with sarcopenia was 
significantly associated with poorer MCS, GH, and BP scores as well 
as poorer scores in all four mental health domains of the SF-36 (i.e. 
VT, RE, SF, and MH). We postulate several possible reasons to explain 
why the association between sarcopenia and HRQoL was lost after 
adjustment for confounders for women in our current study. This 
discrepancy in the quality of life results between males and females 
in our study might be explained by the fact that mediators in the 
relationship between strength and quality of life may be different 
between men and women [25,26]. In women, functional capacity 
(i.e. ability to perform instrumental activities of daily living) has been 
shown to mediate the relationship between strength and quality of life, 
while in men, strength is directly related to quality of life [25]. In the 
study by Beaudart [19], sarcopenic women were significantly more 
impaired for some aspects of the instrumental activities of daily living 
(IADL) such as housekeeping and ability to manage finances compared 
to non-sarcopenic women. In contrast, sarcopenic men do not seem to 
be more dependent in the various aspects of IADL compared with non-
sarcopenic men [19]. There may also be other potential factors leading 
to functional impairment that accounted for the poor quality of life in 
women other than sarcopenia. Life style factors such as smoking and 
low physical activity had been shown to have a greater negative effect on 
HRQoL in women compared to men [27-29]. The Australian study by 
Jayasinghe [27] showed that female smokers had clinically significant 
poorer quality of life in the mental health domain compared to non-
smokers.  Other studies had demonstrated that females with low or no 
physical activity were strong predictors of poorer quality of life [28,29]. 
Medical co-morbidities such as arthritis, diabetes, osteoporosis, and 
cardiovascular disease are also strongly associated with adverse HRQoL 
in women [28]. A study has shown that females who had stroke or 
transient ischaemic attack were significantly more negatively affected 
in their quality of life compared to their male counterparts [26], and 
that this may in part, be mediated by the functional disability after 
stroke [30].
There has only been one longitudinal study investigating the 
relationship between muscle performance and muscle strength and 
quality of life. The Bindawas’ study [31] assessed the association between 
the short physical performance battery (SPPB) and muscle strength 
with the SF-36 quality of life in 621 community dwelling older Mexican 
Americans over a period of six years. SPPB and muscle strength were 
noted to be independent predictors of the SF-36 PCS score at six years 
for both genders [31]. In addition, high total muscle strength was 
significantly associated with slower rate of decline in the MCS scores 
over time. There is therefore a need for longitudinal evaluation of the 
relationship between sarcopenia and quality of life.
Even though the therapeutic role of nutritional intervention alone 
(i.e. protein supplementation) in the management of sarcopenia is 
inconsistent [32], it is postulated that the combined effects of exercise 
training and high quality nutritional supplementation, especially 
with protein supplementation, has a role in preventing and managing 
sarcopenia [33]. However, no studies to date have confirmed the 
benefit of exercise in combination with nutritional supplementation in 
improving quality of life for sarcopenic older people and this is an area 
of research that would benefit from attention [34,35]. 
There are several limitations to this study. Firstly, due to the 
community-based nature of this study, subjects from residential care 
facility or those who were frailer and home- bound were not assessed. 
Male Female
PCS MCS PCS MCS
P–value P–value P - value P - value
Unadjusted
Β = - 10.81
SEʙ = 4.29
β = - 0.138
0.012
Β = - 9.39
SEʙ = 3.04 
β = - 0.165
0.002
Β = - 8.71
SEʙ = 4.61 
β = - 0.103
0.060
Β = - 6.82
SEʙ = 3.49 
β = - 0.102
0.051
Model 1
Β = - 9.16
SEʙ = 4.46 
β = - 0.117
0.041
Β = - 10.59
SEʙ = 3.17
β = - 0.186
0.001
Β = - 4.86
SEʙ = 4.56 
β = - 0.058
0.287
Β = - 4.75
SEʙ = 3.52 
β = - 0.071
0.178
Model 2
Β = - 9.19
SEʙ = 5.20 
β = - 0.112
0.078
Β = - 11.61
SEʙ = 3.65
β = - 0.200
0.002
Β = - 1.12
SEʙ = 4.94 
β = - 0.013
0.821
Β = - 1.84
SEʙ = 3.90 
β = - 0.028
0.637
Model 3
Β = - 8.93
SEʙ = 5.27 
β = - 0.110
0.092
Β = - 11.60
SEʙ = 3.30
β = - 0.202
0.001
Β = 3.24







Table 3. Relationship between sarcopenia and SF-36 quality of life in men and women
Β: Unstandardized regression coefficient, SEʙ: Standard error of the coefficient, β: Standardized coefficient, PCS: physical component summary, MCS: mental component summary, Model 
1: sarcopenia + age, Model 2: model 1 + physical activity + smoking status, Model 3: model 2 + Charlson Co-morbidity Index + depression
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The prevalence of sarcopenia and the likelihood of poorer quality of life 
are likely higher in these population groups. The subjects in this study 
were predominantly Caucasian and therefore not representative of the 
multi-cultural Australian society of today. Therefore, it is important 
that the findings of this study are confirmed in other population groups. 
It would have been ideal to be able to adjust for cognitive status as a 
confounding variable but this was not assessed in this study. Finally, 
as this was a cross-sectional study, the causal relationship between 
sarcopenia and quality of life could not be established. 
Conclusion
This is the first study assessing the association of sarcopenia and 
HRQoL in older Australians. Although there have been two previous 
cross-sectional studies elsewhere on this topic, this study adds to the 
literature as it demonstrated a clear gender difference in regard to the 
impact of sarcopenia on HRQoL in men and women. After adjustment 
for multiple confounders, sarcopenia in men was an independent 
predictor of poorer quality of life. No association between sarcopenia 
and HRQoL was seen in women. It is important to undertake 
longitudinal analysis to determine if sarcopenia predicts poor quality of 
life in older people. It is equally necessary to investigate if interventions 
such as physical activity or protein supplementation can improve 
quality of life in those with sarcopenia.
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